Home > Insider Trading > Filing (0001214659-25-004545)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1677077	Alzamend Neuro Inc.	ALZN	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1333268	B. William Horne	3480 Peachtree Road Ne Second Floor, Suite 103 Atlanta GA 30326		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-03-18	10,000	$0.06	16,666	No	4	M	Direct
Common Stock	Acquisiton	2025-03-18	5,000	$0.97	21,666	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (Right to Buy)	Disposition	2025-03-18	10,000	$0.00	10,000	$0.06

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2026-04-29	No	4	M	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Options (Right to Buy)	$225.00		2029-11-25	1,667	1,667	Direct
Common Stock	Stock Options (Right to Buy)	$225.00		2029-11-17	1,667	1,667	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2029-11-25	1,667	1,667	Direct
2029-11-17	1,667	1,667	Direct

Footnotes

This transaction was effected pursuant to Rule 16b-3 with shares of common stock received upon the exercise of stock options.
The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $0.9703. The range of purchase prices on the transaction date was $0.9693 to $0.9742 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
The stock options exercised in this transaction were fully vested and exercisable as of the transaction date.
The stock options vest ratably over thirty-six (36) months beginning on the date of grant and are fully vested.
None of these performance-based stock options are vested or exercisable.